Abstract
Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.
Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography
Current Gene Therapy
Title: Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Volume: 10 Issue: 5
Author(s): J. Fraser Wright, Jennifer Wellman and Katherine A. High
Affiliation:
Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography
Abstract: Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.
Export Options
About this article
Cite this article as:
Fraser Wright J., Wellman Jennifer and High A. Katherine, Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65, Current Gene Therapy 2010; 10 (5) . https://dx.doi.org/10.2174/156652310793180715
DOI https://dx.doi.org/10.2174/156652310793180715 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights in Specific Cerebellar and Cerebral Activations in Blind Subjects
Current Medical Imaging Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors
Combinatorial Chemistry & High Throughput Screening Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Genetic Basis of Mitochondrial Optic Neuropathies
Current Molecular Medicine Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Abnormal Head Posture due to Ocular Problems- A Review
Current Pediatric Reviews State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Review of Pediatric Uveitis
Current Pediatric Reviews Current Ocular Drug Delivery Challenges for N-acetylcarnosine: Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships
Recent Patents on Drug Delivery & Formulation The Contrast Sensitivity Test in Early Detection of Ocular Changes in the Relation to the Type I Diabetes Mellitus Compensation in Children,Teenagers, and Young Adults
Recent Patents on Inflammation & Allergy Drug Discovery The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Intraocular Lens and Biocompatibility - A Review
Recent Patents on Biomedical Engineering (Discontinued)